Liver function and drug dosing: a key safety study

NCT ID NCT07428525

Completed Knowledge-focused Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Feb 27, 2026 · Last updated May 16, 2026 · Updated 13 times

Summary

This study looked at how the body processes a single dose of the drug AMG 133 in 36 adults with mild, moderate, or severe liver problems compared to those with healthy livers. The goal was to see if liver function changes drug levels and safety. Results will help doctors decide the right dose for patients with liver issues.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Clinical Pharmacology Of Miami, LLC

Miami, Florida, 33172, United States
Orlando Clinical Research Center

Orlando, Florida, 32809, United States
Panax Clinical Research

Miami Lakes, Florida, 33014-2811, United States
Pinnacle Clinical Research San Antonio

San Antonio, Texas, 78229-4801, United States
The Texas Liver Institute, Inc.

San Antonio, Texas, 78215-2100, United States

Conditions

Explore the condition pages connected to this study.

HEPATIC IMPAIRMENT